TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03886870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle and work intervention
Description: The intervention period lasted for a year with three institution-based stays, 4 weeks at baseline and 2 weeks at 6 and 12 months. At baseline, participants got a functional assessment and an individual adjusted rehabilitation plan. At all three stages: The intervention contains activity training with a focus on the joy of movement, strength- and cardio-training. There were lectures and cognitive therapy to promote self-care and lifestyle change. The intervention contained lectures on diet, nutrition and cooking-classes. Participants set goals at baseline and adjusting these during the progress. Exercise programs was designed to use at home. The Cognitive Information Processing model of career guidance was the mainframe for the work dimension. All participants had talks with the work consultant at baseline, 6 and 12 months. Two work lectures, Duties and rights as employees and Work as medicine. When needed the work consultant contacted the employer in order to facilitate changes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: The intervention period lasted for a year with three institution-based stay, 4 weeks at baseline and 2 weeks at 6 and 12 months. At baseline, participants got a functional assessment and an individual adjusted rehabilitation plan.~At all three stages: The intervention contains activity training with focus on joy of movement, strength- and cardio-training. There was lectures and cognitive therapy to promote self-care and lifestyle change. The intervention contained lectures on diet, nutrition and cooking-classes. Participants set goals at baseline and adjusting these during the progress. They developed exercise programs designed to use at home.
Study: NCT04310007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT00898638

Intervention type: OTHER
Intervention: medical chart review
Study: NCT04310007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study: NCT03875781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Arm A : Experimental~* Intervention Type : Drug~* Intervention Name : Modified FOLFIRINOX (experimental arm)~* Intervention Description : preoperative chemotherapy: Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radiochemotherapy
Description: Arm B: Active comparator~* Intervention Name : modified FOLFIRINOX followed by preoperative standardized radiochemotherapy (control arm)~* Intervention Description : preoperative chemotherapy: Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively.followed by preoperative radiochemotherapy with concurrent capecitabine 825 mg/m2/12h 5 days/week and intensity modulated radiation therapy using a simultaneous integrated boost technique with 45 Gy in 25 fractions in pelvic volume and 50 Gy in 25 fractions to the tumor.
Study: NCT04310007

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given PO
Study: NCT03957720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMSA
Description: Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMSA
Description: Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMSA
Description: Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc gluconate
Description: Dosage Form: Zinc gluconate: 140mg per time,Zinc Frequency:BID,Zinc Duration: 5 years; Dosage Form: Zinc gluconate: 140mg per time,Zinc Frequency:TID,Zinc Duration: 5 years; Dosage Form: Zinc gluconate: 210mg per time,Zinc Frequency:TID,Zinc Duration: 5 years;
Study: NCT02755558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low energy density
Description: Low energy density milk served

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low energy density
Description: Low energy density milk served

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High energy density
Description: High energy density milk served

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High energy density
Description: High energy density milk served

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small portion
Description: Small portion of milk served

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small portion
Description: Small portion of milk served

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Large portion
Description: Large portion of milk served

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Large portion
Description: Large portion of milk served
Study: NCT03938389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan Tab 97-103 MG
Description: Participants will take Sacubitril-Valsartan for 26 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 160mg
Description: Participant will take Valsartan for 26 weeks
Study: NCT01954459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insupatch
Description: Device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous site of glucose sensor.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose sensor
Description: Glucose sensor inserted without warming patch
Study: NCT03938389

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Participant with take placebo for 26 weeks or if blood pressure elevated will receive standard of care blood pressure medication, amlodipine.
Study: NCT01772238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml
Description: Reference product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml
Description: Reference product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml
Description: Test product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml
Description: Test product
Study: NCT04848545

Intervention type: OTHER
Intervention: Observational
Description: Prenatal maternal exposure to endocrine disrupting chemicals
Study: NCT01230905

Intervention type: RADIATION
Group type: OTHER
Intervention: PET scan and ultrasound
Description: Nuclear rest/stress testing of the heart using N-13-ammonia paired with brachial artery ultrasound
Study: NCT01308775

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SIS.NET, Routine Follow-up
Description: * SIS.NET - One or two oncology related clinic visits per year (as recommended by the American Society of Clinical Oncology breast cancer follow up guidelines (18)), with additional access to oncology care driven by ongoing review of patient's self reported symptoms through web-based questionnaires.~* Routine follow up care with appointment frequency determined by the treating medical oncologist or oncology/breast surgeon. Patients complete the same web-based symptom questionnaires within 30 days of a scheduled clinic visit but the results are not reviewed until their clinic visit.
Study: NCT04310007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: Given IV
Study: NCT05129605

Intervention type: DIAGNOSTIC_TEST
Intervention: Prostate cancer screening
Description: Physical exam (digital rectal exam), prostate-specific antigen (PSA) and PSA derivatives, and multiparametric MRI of the prostate

Intervention type: DIAGNOSTIC_TEST
Intervention: Prostate cancer screening
Description: Physical exam (digital rectal exam), prostate-specific antigen (PSA) and PSA derivatives, and multiparametric MRI of the prostate

Intervention type: DIAGNOSTIC_TEST
Intervention: Prostate cancer screening
Description: Physical exam (digital rectal exam), prostate-specific antigen (PSA) and PSA derivatives, and multiparametric MRI of the prostate
Study: NCT04058067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab
Description: 5 x every 6 weeks loading then every 12 weeks or every 8 weeks maintenance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: 5 x every 4 weeks loading then every 8 weeks maintenance
Study: NCT04202003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ011133
Description: This is an open-label Phase 1/2a clinical study. The study will be conducted in two parts: Part I: Phase 1 dose escalation, TJ011133 is tentatively scheduled to be administered once weekly in 28-day treatment cycles;Part II: Phase 2a study TJ011133 will be administered at a dose of 30 mg/kg once weekly, and AZA will be administered at a dose of 75 mg/m2 by subcutaneous injection for 7 consecutive days from D1 to D7 in 28-day treatment cycles.
Study: NCT02065856

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVANZ Salsola
Description: AVANZ Salsola
Study: NCT02529644

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Taking It to the Pews (Comparison)
Description: Pastors and Health Action Team members will be trained and receive manualized pastor/church liaison trainings on study procedures, HIV basics and local resources and coordination of HIV screening events. Comparison churches will receive: a) non-tailored project materials (videos, brochures) collected from health organizations and b) standard, non-tailored activities (e.g., community-based HIV testing events) coordinated by their church liaisons. The comparison churches will offer 3 HIV screening events and deliver 1-2 standard materials per month for the 12 month study period. All comparison churches will receive all Taking It to the Pews HIV Tool Kit materials after the completion of 12-month assessments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taking It to the Pews (Experimental)
Description: Pastors and Health Action Team members will be trained in treatment implementation procedures using the scripted, study implementation manual. Intervention churches will receive the TIPS HIV Tool Kit, including a study manual. These churches will hold a Kick-off event, where tools will be distributed, and motivational strategies implemented. After the Kick-off, liaisons will deliver 1-2 Tool Kit materials/activities per month through targeted multilevel church activities minimum of 24 tools over the 12 month study period. Two additional HIV screening events will be planned (one for community members) and will be open to all persons seeking screening, including study nonparticipants. Both groups will receive manualized pastor/church liaison trainings on study procedures, HIV basics and local resources and coordination of HIV screening events.
Study: NCT03749083

Intervention type: OTHER
Intervention: The Functional Assessment of Cancer Therapy- Colorectal
Description: The Functional Assessment of Cancer Therapy- Colorectal (FACT-C) questionnaire measures health-related quality of life for people with chronic illnesses.
Study: NCT01780337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Intranasal dose of 20 IU oxytocin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intranasal dose of saline
Study: NCT01127464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCVax-001
Description: Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCVax-001
Description: Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCVax-001
Description: Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
Study: NCT03951493

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid 4Mg Solution for Injection + Hypo-fractured radiotherapy in stereotactic conditions
Description: All patients receive radiotherapy i.e. treatment on D1, D3 and D5.~Several radiotherapy schemes are possible:~* 20 Gy in 1 fraction;~* 27 Gy in 3 fractions of 9 Gy~* 30 Gy in 5 fractions of 6 Gy. All patients in the experimental arm receive an intravenous injection of at least 15 minutes of 4 mg zoledronic acid every month for 12 months.~The first injection must be made no more than 3 weeks before the first day of radiotherapy. It can be performed up to J1 of radiotherapy.~The injections will be carried out either at the patient's home by the nurses or in the investigator centre.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypo-fractured radiotherapy in stereotactic conditions
Description: All patients receive radiotherapy i.e. treatment on D1, D3 and D5.~Several radiotherapy schemes are possible:~* 20 Gy in 1 fraction;~* 27 Gy in 3 fractions of 9 Gy~* 30 Gy in 5 fractions of 6 Gy.
Study: NCT00668382

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha-Gal Glycosphingolipid
Description: Intra-tumoral injection of Alpha-Gal Glycosphingolipid to evaluate toxicity
Study: NCT04322331

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT04004221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg intravenously (IV) every 3 weeks (Q3W)
Study: NCT02713386

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate
Description: Given PO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo TRS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo TRS
Study: NCT04470050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Sublingual Film of Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Sublingual Film of Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Sublingual Film of Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Sublingual Film of Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Sublingual Film of Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Sublingual Film of Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sublingual Placebo film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sublingual Placebo film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sublingual Placebo film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sublingual Placebo film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sublingual Placebo film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sublingual Placebo film
Study: NCT03013387

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 90Y-DOTA-3-tyr-Octreotide
Description: 90Y-DOTATOC is a radiopharmaceutical that will be used l as a treatment for both children and adults with neuroendocrine and other somatostatin receptor positive tumors.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) whole body scan
Description: 68Ga-DOTATOC is a radiopharmaceutical used in PET scans to identify tumors as it can adhere to Somatostatin Receptors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amino Acids
Description: This is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing radiation dose to the kidneys.
Study: NCT03776669

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy + Hiatal hernia repair
Description: To evaluate the role of concomitant hiatal hernia repair in laparoscopic sleeve gastrectomy for morbidly obese patients.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy alone
Description: Current mainstay and standard surgical treatment for morbidly obese patients.
Study: NCT01581021

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pedicle screws
Description: Screws that are placed into the pedicle of vertebral body.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laminar Hooks
Description: Hooks are placed over the lamina of the vertebral body
Study: NCT04377321

Intervention type: DRUG
Intervention: Colchicine Tablets
Description: colchicine tabletes for 6 months
Study: NCT02573311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin hydrochloride
Study: NCT03888612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV-110
Description: Part A: Daily oral dosages are predetermined by cohort review committee after the initial starting dose cohort after the first 28 days of treatment~Part B: Daily oral dosage and schedule at a recommended Phase 2 dose based on data from Part A
Study: NCT04377321

Intervention type: DRUG
Intervention: Colchicine Tablets
Description: colchicine tabletes for 6 months

Intervention type: DRUG
Intervention: Colchicine Tablets
Description: colchicine tabletes for 6 months
Study: NCT01198704

Intervention type: OTHER
Intervention: search of factors predicting tumor recurrence
Description: Morphological, chronological, anatomy-pathological and molecular search
Study: NCT06791642

Intervention type: DEVICE
Intervention: Laparoscopic Parastomal Hernia Repair Using the Sandwich Technique
Description: The sandwich technique was performed laparoscopically according to minimally invasive principles. Pneumoperitoneum was typically established using a Veress needle if the subcostal region was free from previous surgical scarring. For patients with prior extensive abdominal surgeries, a small laparotomy was performed to place the first 10-mm trocar directly under vision, ensuring safe entry into the peritoneal cavity. A 30° laparoscope was used throughout the procedure for enhanced visualization of the operative field.~Trocar placement was designed to optimize access and ergonomics. The primary trocar was placed either in the periumbilical region or in the left or right flank, depending on the patient's anatomy and stoma location. Mesh used:1. Parietex™ Composite Mesh (Medtronic, USA): A multifilament polyester mesh with an anti-adhesive collagen barrier to minimize visceral adhesions.

Intervention type: DEVICE
Intervention: Laparoscopic Parastomal Hernia Repair Using the Sandwich Technique
Description: The sandwich technique was performed laparoscopically according to minimally invasive principles. Pneumoperitoneum was typically established using a Veress needle if the subcostal region was free from previous surgical scarring. For patients with prior extensive abdominal surgeries, a small laparotomy was performed to place the first 10-mm trocar directly under vision, ensuring safe entry into the peritoneal cavity. A 30° laparoscope was used throughout the procedure for enhanced visualization of the operative field.~Trocar placement was designed to optimize access and ergonomics. The primary trocar was placed either in the periumbilical region or in the left or right flank, depending on the patient's anatomy and stoma location. Mesh use Synecor™ Hybrid Mesh (BD, USA): A macroporous mesh combining polypropylene with a bioresorbable layer that degrades over time, leaving a durable support structure to promote tissue integration.